Introducing the LeXso Hybrid System
Breaking the Speed Barrier in Liquid Biopsy: Introducing the LeXso Hybrid System
By LexigenBio Scientific Team
In the race against cancer, time and sensitivity are our most valuable assets. While Next-Generation Sequencing (NGS) has revolutionized our ability to detect mutations, traditional targeted capture methods often act as a bottleneck—requiring long hybridization times (often 16+ hours) and complex workflows that can delay critical clinical insights.
To address these challenges, LexigenBio is proud to showcase our LeXso Hybrid System. This exclusive, patented technology is engineered specifically for the ultra-sensitive demands of liquid biopsy, Minimal Residual Disease (MRD) monitoring, and early cancer detection.
The LeXso Difference: Patented Speed and Precision
Traditional hybridization capture relies on 120 nt probes and lengthy incubation periods to ensure binding. The LeXso Hybrid System reimagines this process from the ground up. By utilizing a unique architecture of 20–100 nt DNA probes and optimized buffer chemistry, LeXso achieves superior enrichment in a fraction of the time.
Key Technological Highlights:
- No Concentration Required: Unlike traditional methods that require time-consuming vacuum concentration of libraries, LeXso works directly with your pre-libraries, preserving sample integrity and saving hours of lab work.
- Rapid Kinetics: Hybridization is completed in just 1 hour, with a capture step that takes only 10 minutes.
- Unmatched Sensitivity: Specifically designed for “small-but-mighty” panels (up to 100 Kb), LeXso excels at pulling out rare signals from a sea of background noise.
Comparison: Why LeXso is the New Standard for Clinical Labs
| Feature | Traditional Hybridization | LeXso Hybrid System |
|---|---|---|
| Probe Length | 120 nt | 20–100 nt (Optimized) |
| Hybridization Time | 16 hours (Overnight) | 1 hour |
| Capture Time | 45 minutes | 10 minutes |
| Total Capture TAT | ~19 hours | ~2.5 – 3.5 hours |
| Concentration Step | Required | None |
Empowering High-Value Clinical Applications
The LeXso Hybrid System isn’t just about speed; it’s about enabling the most difficult NGS applications with high-fidelity data.
1. Minimal Residual Disease (MRD) Monitoring
In MRD, we are looking for the “needle in the haystack.” LeXso’s high-sensitivity capture ensures that low-abundance circulating tumor DNA (ctDNA) is enriched effectively, allowing for the early detection of relapse when it is most treatable.
2. Cancer Early Detection & Screening
By pairing LeXso with our LeXDual technology, labs can synchronously detect methylation and mutation signals in a single day. This “panoramic” view of the genome is essential for robust early screening assays.
3. Targeted mNGS (Infectious Disease)
For pathogens where every hour counts, the LeXso Respiratory Pathogen (RP) Solution can move from sample to insight in just 13.5 hours, providing a comprehensive view that traditional culture methods simply cannot match.
Seamless Integration with LeXBot Automation
To ensure reproducibility at scale, the LeXso Hybrid System is fully optimized for the LeXBot Automation Series. This combination allows for a “walk-away” workflow, reducing manual intervention and human error while maximizing laboratory throughput.
Conclusion: The Future of Precision Medicine is Fast
The LeXso Hybrid System represents a fundamental shift in how we approach targeted NGS. By eliminating the overnight bottleneck and enhancing sensitivity for rare variants, LexigenBio is empowering clinicians and researchers to act faster and with greater confidence.
Experience the LeXso advantage today. [Request a Technical Consultation] | [01-Brochure-product overview-250827A] | [Contact support@lexigenbio.com]
Ordering Information:
- LX15201: LeXso Hybrid Capture Reagents v2 (96 rxn)
- LX16101: LeXso Blockers (for Illumina)
- LX11340: LeXDual Beta Panel (specifically optimized for LeXso)
Visit www.lexigenbio.com to explore our full range of LeXso-powered panels.